Business
Preliminary Results and Notice of AGM
Oxford BioDynamics Plc reported total revenue of £1.1 million for the year ended 30 September 2025, a significant increase from £0.6 million in the prior year, driven by clinical test revenue that more than doubled to £1.1 million. The company reduced its operating loss to £11.1 million from £12.9 million in the previous year, while cash and cash equivalents stood at £1.4 million. Post-year end, Oxford BioDynamics successfully raised £7 million to fund ongoing operations, following a £7.35 million fundraising earlier in the year. The company also noted continued growth in its EpiSwitch Prostate Screening (PSE) test orders, which more than doubled to approximately 1,900. Disclaimer*
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n\nOxford Biodynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nPreliminary results for the year ended 30 September 2025\nand\nNotice of Annual General Meeting\n \nOxford, UK - 16 December 2025 - Oxford BioDynamics Plc (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, today announces its final results for the year ended 30 September 2025.\nCorporate and operational highlights\n§ Appointment of Iain Ross as Executive Chairman (January 2025)\n§ PSE orders more than doubled on prior year (to ~1,900, FY24: ~725)\n§ Real-world data on EpiSwitch® CiRT in liver and GI cancers presented at ASCO-GI (January 2025)\n§ Peer-reviewed publication of research supporting OBD's EpiSwitch® NST for colorectal cancer (February 2025)\n§ Visit to OBD's Oxford HQ by former UK Prime Minister, Rt Hon Rishi Sunak in his role as an Ambassador for Prostate Cancer Research (February 2025)\n§ Accreditation of UK clinical lab (May 2025)\n§ Collaboration with Google Cloud (August 2025)\nFinancial highlights\n§ Total revenue of £1.1m (FY24: £0.6m)\n§ Clinical test revenue 2.7x prior year at £1.1m (FY24: £0.4m)\n§ Operating loss of £11.1m (FY24: £12.9m)\n§ Fundraising generating £7.35m (before costs) (February 2025)\n§ Cash and cash equivalents and fixed-term deposits of £1.4m as at 30 September 2025 (FY24: £2.8m)\nPost-year end highlights\n§ Fundraising generating £7m (before costs) to fund the ongoing business (November 2025)\n§ Development of breakthrough diagnostic test for Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME) (October 2025)\n§ Commenced third party discussions regarding the evaluation of and investment in EpiSwitch® Orion\n§ Continued successive record months of PSE orders to November 2025\n \n \nIain Ross, Executive Chairman of OBD said:\n\"Since joining OBD in January this year, I have been impressed with the extraordinary depth and breadth of the technology and capabilities within the business. This has been an exciting period of renewal, and it is encouraging to see revenue-generating and cost-saving initiatives starting to deliver. Monthly orders for our EpiSwitch PSE test have more than doubled over the past year, highlighting the growing clinical...